Kaxi Yu, Shuai Chen, Chander Amgoth, Guping Tang, Hongzhen Bai and Xiurong Hu
CrystEngComm, 2021,23, 2923-2927
DOI:
10.1039/D1CE00175B,
Communication
Two polymorphic phases of the antiviral drug remdesivir (RDV), namely RDV-I and RDV-II are prepared and structurally characterized by single-crystal X-ray diffraction. Both RDV-I and RDV-II are solvent-free but exhibit different packing patterns in their crystals. RDV-I and RDV-II feature different pharmacokinetics, as revealed by in vitro and in vivo studies. This work highlights the significance of remdesivir drug formulations on the pharmacokinetics and ultimately patient outcome when combating the coronavirus disease 2019 (Covid-19).